Plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: Relationship to stroke risk factors

Circulation

Volumn 106, Issue 15, 2002, Pages 1962-1967

  Conway, Dwayne S G ^a   Pearce, Lesly A ^a   Chin, Bernard S P ^a   Hart, Robert G ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Fibrillation, atrial; Risk factors; Soluble P selectin; Stroke; Von Willebrand factor

Indexed keywords

PADGEM PROTEIN; VON WILLEBRAND FACTOR;

ADULT; AGE; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ENDOTHELIUM INJURY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE DYSFUNCTION; THROMBOGENESIS; VALIDATION PROCESS;

AGED; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOLYTIC AGENTS; HEART VALVES; HUMANS; MALE; P-SELECTIN; PLATELET ACTIVATION; RISK FACTORS; VON WILLEBRAND FACTOR;

EID: 0037044431     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000033220.97592.9A     Document Type: Article

References (34)

1. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N-9N.
2. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
3. Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke. 2001;32:803-808.
4. Gustafsson C, Blomback M, Britton M, et al. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke. 1990;21:47-51.
5. Kumagai K, Fukunami M, Ohmori M, et al. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol. 1990;16:377-380.
6. Li-Saw-Hee FL, Blann AD, Lip GYH. A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillation. J Am Coll Cardiol. 2000;35:1926-1931.
7. Lip GYH, Lowe GD, Rumley A, et al. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J. 1995;73:527-533.
8. Sohara H, Amitani S, Kurose M, et al. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 1997;29:106-112.
9. Feinberg WM, Pearce LA, Hart RG, et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke. 1999;30:2547-2553.
10. Ono N, Koyama T, Suehiro A, et al. Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction. Int Angiol. 1992;11:298-303.
11. Pongratz G, Brandt-Pohlmann M. Henneke KH, et al. Platelet activation in embolic and preembolic status of patients with nonrheumatic atrial fibrillation. Chest. 1997;111:929-933.
12. Feng D, D'Agostino RB, Silbershatz H, et al. Hemostatic state and atrial fibrillation (the Framingham Offspring Study). Am J Cardiol. 2001;87:168-171.
13. Blann AD, Lip GYH, Beevers DG. et al. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost. 1997;77:1077-1080.
14. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA. 1998;279:1273-1277.
15. Feinberg WM, Kronmal RA, Newman AB, et al. Stroke risk in an elderly population with atrial fibrillation. J Gen Intern Med. 1999;14:56-59.
16. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
17. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-638.
18. Asinger RW, Koehler J, Pearce LA, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation, II: dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr. 1999;12:1088-1096.
19. Goldman ME, Pearce LA, Hart RG, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation, I: reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr. 1999;12:1080-1087.
20. Zabalgoitia M, Halperin JL, Pearce LA, et al. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation: Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol. 1998;31:1622-1626.
21. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med. 1998;128:639-647.
22. Blackshear JL, Pearce LA, Hart RG, et al. Aortic plaque in atrial fibrillation: prevalence, predictors, and thromboembolic implications. Stroke. 1999;30:834-840.
23. Michelson AD, Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A. 1996; 93:11877-11882.
24. Fijnheer R, Frijns CJ, Korteweg J, et al. The origin of P-selectin as a circulating plasma protein. Thromb Haemost. 1997;77:1081-1085.
25. Jilma B, Eichler HG. Vondrovec B, et al. Effects of desmopressin on circulating P-selectin. Br J Haematol. 1996;93:432-436.
26. Ware RE, Parker RI, McKeown LP, et al. A human chimera for von Willebrand disease following bone marrow transplantation. Am J Pediatr Hematol Oncol. 1993;15:338-342.
27. Li-Saw-Hee FL, Blann AD, Lip GYH. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke. 2000;31:828-833.
28. Blann AD, Lanza F, Galajda P, et al. Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis: the influence of aspirin and cigarette smoking. Thromb Haemost. 2001;86:777-783.
29. Lip GYH, Lip PL, Zarifis J, et al. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation: effects of introducing ultra-low-dose warfarin and aspirin. Circulation. 1996;94:425-431.
30. Blann AD, Daly RJ, Amiral J. The influence of age, gender and ABO blood group on soluble endothelial cell markers and adhesion molecules. Br J Haematol. 1996;92:498-500.
31. Barbaux SC, Blankenberg S, Rupprecht HJ, et al. Association between P-selectin gene polymorphisms and soluble P-selectin levels and their relation to coronary artery disease. Arterioscler Thromb Vasc Biol. 2001;21:1668-1673.
32. Fukuchi M, Watanabe J, Kumagai K, et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coil Cardiol. 2001;37:1436-1442.
33. Goldsmith I, Kumar P, Carter P, et al. Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study. Am Heart J. 2000;140:777-784.
34. Heppell RM, Berkin KE, McLenachan JM, et al. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart. 1997;77:407-411.